What's behind Exact Sciences' hot year? — 4 analyst insights

Written by Eric Oliver | July 09, 2019 | Print  |

Exact Sciences continues to have a strong year, which left one Motley Fool analyst asking, "Why?"

What you need to know:

1. The analyst attributes Exact's growth largely to the increased sales of Cologuard. Sales took off after Exact entered into a marketing and promotional partnership with Pfizer in 2018.

2. Those sales — as well as Exact's developmental work on liquid biopsy tests with Rochester, Minn.-based Mayo Clinic — have some analysts believing the company could be an acquisition target. However, its most likely suitor, Pfizer, recently made a $10.6 billion acquisition, which leads Motley Fool analysts to speculate that any acquisition talks are on hold.

3. Analysts believe Cologuard will pass $1 billion in sales in 2020, which is fueling the company's high valuation.

4. However, Exact's monopolistic grasp on the market, and in turn its valuation, could fall off if competitors succeed in bringing tests to the market.

More articles on gastroenterology:
3 things to know about outpatient cervical disc replacement
10 things to know about spine surgery for ASCs in 2019
Outpatient revision minimally invasive lumbar decompression: 4 notes on ASC vs. HOPD

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.